🏢 Novo Nordisk $NOVO B (-1,98%)
$NVO (-1,61%) presents new study results on amycretin presented
⚗️ Up to 24% weight loss in overweight and obese adults
💉 Administration:
- Weekly injections:
- 20 mg ➔ 22 % weight loss (after 36 weeks)
- 60 mg ➔ 24.3 % weight loss
- Daily tablet:
- 50 mg ➔ 10.4 % weight loss (after 12 weeks)
- 100 mg ➔ 13.1 % weight loss
🔬 Dual mode of action:
- GLP-1 mimic (like Wegovy)
- Amylin receptors for additional hunger management
🤢 Side effects: mainly gastrointestinal complaints, comparable to other weight loss medications
📅 Phase 3 trials to start in 2026, followed by possible approval
🩺 Experts emphasize: Cardiovascular risks and comorbidities remain important
🔬 Further studies needed for direct comparison with existing drugs such as Ozempic
Source:
https://de.tradingview.com/news/reuters.com,2025:newsml_L8N3SN1L8:0/